Progynova Drug Interactions

Hormonal contraception should be stopped when HRT is started and the patient should be advised to take nonhormonal contraceptive precautions, if required.
Drugs: Long-term treatment with hepatic enzyme-inducing drugs (eg, several anticonvulsants and antimicrobials) can increase the clearance of sex hormones and may reduce clinical efficacy. Such hepatic enzyme-inducing properties have been established for hydantoins, barbiturates, primidone, carbamazepine and rifampicin, and are also suspected for oxcarbazepine, topiramate, felbamate and griseofulvin. Maximal enzyme induction is generally not seen before 2-3 weeks but may then be sustained for at least 4 weeks after the cessation of drug therapy.
In rare cases, reduced estradiol levels have been observed under the simultaneous use of certain antibiotics (eg, penicillins and tetracycline).
Substances which undergo substantial conjugation (eg, paracetamol) may increase the bioavailability of estradiol by competitive inhibition of the conjugation system during absorption.
In individual cases, the requirement for oral antidiabetics or insulin can change as a result of the effect on glucose tolerance.
Alcohol: Acute alcohol ingestion during use of HRT may lead to elevations in circulating estradiol levels.
Laboratory Tests: The use of sex steroids may influence biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins eg, corticosteroid-binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis.
Incompatibilities: None